Xtant Medical Q3 revenue $33.3M (+19% YoY); net income $1.3M vs loss

Xtant Medical Holdings, Inc.

2025-Q3 EPS reported $0.03 vs consensus -$0.01 ▲ beat (+688.2%)

Revenue $33.3M (19% YoY); gross margin 66.1% vs 58.4%; net income $1.3M ($0.01 EPS) vs loss $5.0M (-$0.04 EPS).
Adjusted EBITDA $4.5M vs loss $1.0M in prior year quarter; cash from operations $4.6M (vs $1.7M used).
FY25 revenue guidance reiterated $131-135M (+11-15% YoY).
Pending sale of non-core Coflex/CoFix assets and OUS businesses to Companion Spine expected to close by year-end 2025.
Launched CollagenX bovine collagen particulate for surgical wound closure; potential across entire biologics portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.